Low risk of treatment resistance in Down syndrome with Kawasaki disease

A Japanese nationwide survey has reported that Down syndrome (DS) is a less‐frequently occurring comorbidity in Kawasaki disease (KD). Although altered immune responses are frequently observed in DS, no studies have focused on the treatment response and risk for coronary artery abnormalities (CAA) in DS patients with KD. The aim of this study was therefore to evaluate the clinical manifestations, treatment response and prevalence of CAA in DS with KD.

[1]  K. Kotani,et al.  Time course of cardiac lesions due to Kawasaki disease in Japan: 22nd nationwide survey (2011–2012) , 2016, Pediatrics International.

[2]  J. Sidney,et al.  Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease , 2015, Autoimmunity.

[3]  S. Hasegawa,et al.  Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease , 2015, Pediatric Research.

[4]  A. Tedeschi,et al.  Down syndrome, autoimmunity and T regulatory cells , 2012, Clinical and experimental immunology.

[5]  T. Hara,et al.  Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial , 2012, The Lancet.

[6]  M. Weijerman,et al.  Increased Pro-inflammatory Cytokine Production in Down syndrome Children Upon Stimulation with Live Influenza A Virus , 2012, Journal of Clinical Immunology.

[7]  J. Borghans,et al.  Decreased Thymic Output Accounts for Decreased Naive T Cell Numbers in Children with Down Syndrome , 2011, The Journal of Immunology.

[8]  Tomio Kobayashi,et al.  External Validation of a Risk Score to Predict Intravenous Immunoglobulin Resistance in Patients With Kawasaki Disease , 2011, The Pediatric infectious disease journal.

[9]  Toshiro Hara,et al.  CD25+CD4+ regulatory T cells in patients with Kawasaki disease. , 2004, The Journal of pediatrics.

[10]  S. Rasmussen,et al.  Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study , 2002, The Lancet.

[11]  E. Courchesne,et al.  Protocols to establish genotype-phenotype correlations in Down syndrome. , 1991, American journal of human genetics.

[12]  J. Dacre,et al.  Arthritis in Down's syndrome. , 1988, Annals of the rheumatic diseases.

[13]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[14]  Y. Okuno,et al.  with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease , 2013 .

[15]  平林 優.  Lack of CD4⁺CD25⁺FOXP3⁺ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease , 2013 .

[16]  Yusuke Nakamura,et al.  ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms , 2008, Nature Genetics.

[17]  E. Porcellini,et al.  Altered vessel signalling molecules in subjects with Downs syndrome. , 2006, International journal of immunopathology and pharmacology.

[18]  古野 憲司.  CD25[+]CD4[+] regulatory T cells in patients with Kawasaki disease , 2006 .

[19]  T Enright,et al.  Kawasaki syndrome. , 1990, Annals of allergy.

[20]  W. Watters,et al.  Multiple dislocations of the cervical spine in a patient with juvenile rheumatoid arthritis and Down's syndrome. , 1982, Clinical orthopaedics and related research.

[21]  M. Mikkelsen.  Epidemiology of trisomy 21: population, peri- and antenatal data. , 1981, Human genetics. Supplement.